Pacific Biosciences of California, Inc.
NASDAQ:PACBMedical - Devices
+$0.04 today
- Market cap
- $571.39M
- Beta
- 2.32
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.42
Volume 15.30M
Average 6.06M
PACB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Pacific Biosciences of California, Inc.NASDAQ: PACB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $4.07M fell 98.9% year over year, behind the -95.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 12.6% from the prior quarter. Over 3 fiscal years it compounded at +181.5% a year.
Context
- Depreciation & amortization amounted to 241.5% of revenue in FY2025, up 206.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.9% toward the trailing-twelve-month pace of -95.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 386.41M USD
- Year-over-year change
- +624.5%
- 4-year CAGR
- +140.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 386.41M | +624.5% |
| FY2024 | 2024-12-31 | 53.34M | +63.2% |
| FY2023 | 2023-12-31 | 32.69M | +88.8% |
| FY2022 | 2022-12-31 | 17.32M | +49.5% |
| FY2021 | 2021-12-31 | 11.59M | — |
Depreciation & Amortization vs competitors
How PACB compares with its peers on the latest reported figures
- PACB's LTM Mar 2026 depreciation & amortization of $17.69M is the 2nd largest of the 3 companies compared; the peer median is $138.88M.
- Its year-over-year change of -95.7% is the lowest of 3, against a peer median of +2.5%.
- Depreciation & amortization amounts to 11.1% of revenue for PACB, versus a peer median of 131.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $273M | -1.8% | -11.8% | 6.1% | |
| LTM Mar 2026 | $17.69M | -95.7% | +181.5% | 11.1% | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
| Peer median (excluding PACB) | $138.88M | +2.5% | +4.0% | 131.6% | |
Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (181.22M) | (314.25M) | (306.74M) | (309.85M) | (546.38M) |
| Depreciation & Amortization | 11.59M | 17.32M | 32.69M | 53.34M | 386.41M |
| Deferred Income Tax | (93.65M) | 0 | (11.42M) | (205K) | (546K) |
| Stock-Based Compensation | 80.73M | 78.61M | 0 | 0 | 41.67M |
| Change in Working Capital | 21.01M | (53.97M) | (58.96M) | (40.58M) | 4.44M |
| Accounts Receivables | (7.17M) | 5.46M | (17.83M) | 9.09M | (7.92M) |
| Inventory | (12.43M) | (33.91M) | (13.84M) | (8.32M) | (1.42M) |
| Accounts Payables | 6.36M | 1.03M | 206K | 1.41M | 2.48M |
| Other Working Capital | 34.24M | (26.55M) | (27.49M) | (42.75M) | 11.3M |
| Other Non-Cash Items | 50.37M | 9.08M | 77.88M | 91.24M | 3.19M |
| Operating Cash Flow | (111.18M) | (263.21M) | (266.55M) | (206.06M) | (111.21M) |
| Capital Expenditures | (5.93M) | (16.93M) | (8.84M) | (6.19M) | (2.71M) |
| Acquisitions (Net) | (319.79M) | 179K | (102K) | 0 | 0 |
| Purchases of Investments | (988.05M) | (442.79M) | (756.57M) | (498.64M) | (216.91M) |
| Sales of Investments | 635.24M | 575.8M | 770.12M | 628.83M | 340.07M |
| Other Investing Activities | 0 | (179K) | 0 | 0 | (5M) |
| Investing Cash Flow | (678.53M) | 116.08M | 4.6M | 124M | 115.45M |
| Debt Repayment | 895.18M | (1.61M) | (1.84M) | (50.69M) | 0 |
| Common Stock Issued | 294.85M | 11.23M | 204.52M | 7.7M | 3.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.44M) | 0 | (86.41M) | 0 | 0 |
| Financing Cash Flow | 1.17B | 9.62M | 116.27M | (42.99M) | 3.43M |
| Effect of Forex Changes | 0 | 0 | 500K | 890K | 0 |
| Net Change in Cash | 379.87M | (137.51M) | (145.18M) | (124.15M) | 7.67M |
| Free Cash Flow | (117.11M) | (280.14M) | (275.39M) | (212.25M) | (113.92M) |
Pacific Biosciences of California, Inc.
NASDAQ:PACB
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.